Effectiveness of Tofacitinib in Ulcerative Proctitis Compared to Left Sided Colitis and Pancolitis.
Clinical remission
Tofacitinib
Ulcerative colitis
Ulcerative proctitis
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
received:
31
08
2023
accepted:
03
01
2024
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
15
2
2024
Statut:
aheadofprint
Résumé
Ulcerative proctitis (UP), though associated with high symptom burden and poor quality of life, is excluded from most of the randomized controlled trials in UC, including the OCTAVE trials. We aimed to analyse the effectiveness of tofacitinib in UP, and compare it to that in left sided colitis (LSC) and pancolitis (PC). This was a prospective cohort study. Patients with either steroid-dependent or refractory ulcerative colitis, who received tofacitinib, were divided into three groups based on the disease extent [UP, LSC and PC]. The primary outcome was comparison of proportion of patients in clinical remission in the three groups, at weeks 8, 16 and 48. Safety outcomes were reported using incidence rate per patient year of exposure. Clinical remission was achieved in 47%(15/32), 24%(23/94), and 43%(23/54) of patients at week 8, 56%(18/32), 37%(35/94), and 56%(30/54) of patients at week 16, and 59%(19/32), 38%(36/94), and 24%(13/54) of patients at week 48 in groups UP, LSC and PC, respectively. Corticosteroid-free clinical remission rates were significantly higher in patients in groups UP at week 48. Five (15%) patients with UP were primary non-responders to tofacitinib at week 16, while three (9%) patients had secondary loss of response at week 48. The probability of sustained clinical response was highest in patients with UP. Patients with UP had the lowest incidence of adverse effects. The effectiveness of tofacitinib in inducing and maintaining clinical remission is greater in patients with UP compared to LSC and PC.
Sections du résumé
BACKGROUND
BACKGROUND
Ulcerative proctitis (UP), though associated with high symptom burden and poor quality of life, is excluded from most of the randomized controlled trials in UC, including the OCTAVE trials. We aimed to analyse the effectiveness of tofacitinib in UP, and compare it to that in left sided colitis (LSC) and pancolitis (PC).
METHODS
METHODS
This was a prospective cohort study. Patients with either steroid-dependent or refractory ulcerative colitis, who received tofacitinib, were divided into three groups based on the disease extent [UP, LSC and PC]. The primary outcome was comparison of proportion of patients in clinical remission in the three groups, at weeks 8, 16 and 48. Safety outcomes were reported using incidence rate per patient year of exposure.
RESULTS
RESULTS
Clinical remission was achieved in 47%(15/32), 24%(23/94), and 43%(23/54) of patients at week 8, 56%(18/32), 37%(35/94), and 56%(30/54) of patients at week 16, and 59%(19/32), 38%(36/94), and 24%(13/54) of patients at week 48 in groups UP, LSC and PC, respectively. Corticosteroid-free clinical remission rates were significantly higher in patients in groups UP at week 48. Five (15%) patients with UP were primary non-responders to tofacitinib at week 16, while three (9%) patients had secondary loss of response at week 48. The probability of sustained clinical response was highest in patients with UP. Patients with UP had the lowest incidence of adverse effects.
CONCLUSION
CONCLUSIONS
The effectiveness of tofacitinib in inducing and maintaining clinical remission is greater in patients with UP compared to LSC and PC.
Identifiants
pubmed: 38358458
doi: 10.1007/s10620-024-08276-1
pii: 10.1007/s10620-024-08276-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol,. 2005;19:5 Suppl A-36A. https://doi.org/10.1155/2005/269076 .
doi: 10.1155/2005/269076
Satsangi J, Silverberg MS, Vermeire S, Colombel J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753. https://doi.org/10.1136/gut.2005.082909 .
doi: 10.1136/gut.2005.082909
pubmed: 16698746
pmcid: 1856208
Dubois E, Moens A, Geelen R, Sabino J, Ferrante M, Vermeire S. Long-term outcomes of patients with ulcerative proctitis: analysis from a large referral centre cohort. United Eur Gastroenterol J. 2020;8:933–941. https://doi.org/10.1177/2050640620941345 .
doi: 10.1177/2050640620941345
Meucci G, Vecchi M, Astegiano M et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000;95:469–473. https://doi.org/10.1111/j.1572-0241.2000.t01-1-01770.x .
doi: 10.1111/j.1572-0241.2000.t01-1-01770.x
pubmed: 10685752
Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476. https://doi.org/10.1056/NEJMoa050516 .
doi: 10.1056/NEJMoa050516
pubmed: 16339095
Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710. https://doi.org/10.1056/NEJMoa1215734 .
doi: 10.1056/NEJMoa1215734
pubmed: 23964932
Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–1214. https://doi.org/10.1056/NEJMoa1900750 .
doi: 10.1056/NEJMoa1900750
pubmed: 31553833
Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787. https://doi.org/10.1136/gut.2010.221127 .
doi: 10.1136/gut.2010.221127
pubmed: 21209123
Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265. https://doi.org/10.1053/j.gastro.2011.10.032 .
doi: 10.1053/j.gastro.2011.10.032
pubmed: 22062358
Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736. https://doi.org/10.1056/NEJMoa1606910 .
doi: 10.1056/NEJMoa1606910
pubmed: 28467869
Lucaciu LA, Constantine-Cooke N, Plevris N et al. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211064004. https://doi.org/10.1177/17562848211064004 .
doi: 10.1177/17562848211064004
pubmed: 34987608
pmcid: 8721385
Ma C, Panaccione R, Xiao Y et al. REMIT-UC: real world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis. Am J Gastroenterol. 2022. https://doi.org/10.14309/ajg.0000000000002129 .
doi: 10.14309/ajg.0000000000002129
pubmed: 36799889
pmcid: 10144327
Chaparro M, Garre A, Mesonero F et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA Registry. J Crohns Colitis. 2021;15:35–42. https://doi.org/10.1093/ecco-jcc/jjaa145 .
doi: 10.1093/ecco-jcc/jjaa145
pubmed: 32969471
Honap S, Chee D, Chapman TP et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14:1385–1393. https://doi.org/10.1093/ecco-jcc/jjaa075 .
doi: 10.1093/ecco-jcc/jjaa075
pubmed: 32280965
Lair-Mehiri L, Stefanescu C, Vaysse T et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020;52:268–273. https://doi.org/10.1016/j.dld.2019.10.003 .
doi: 10.1016/j.dld.2019.10.003
pubmed: 31732444
Raine T, Bonovas S, Burisch J et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2–17. https://doi.org/10.1093/ecco-jcc/jjab178 .
doi: 10.1093/ecco-jcc/jjab178
pubmed: 34635919
Sahami S, Wildenberg ME, Koens L et al. Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation: Short-Term Results of the PASSION Study. J Crohns Colitis. 2019;13:165–171. https://doi.org/10.1093/ecco-jcc/jjy127 .
doi: 10.1093/ecco-jcc/jjy127
pubmed: 30285094
Amiot A, Bouguen G, Bonnaud G et al. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Dig Liver Dis. 2021;53:35–43. https://doi.org/10.1016/j.dld.2020.10.018 .
doi: 10.1016/j.dld.2020.10.018
pubmed: 33160886
Sood A, Ahuja V, Midha V et al. Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intest Res. 2020;18:355–378. https://doi.org/10.5217/ir.2019.09176 .
doi: 10.5217/ir.2019.09176
pubmed: 32646198
pmcid: 7609395
Singh A, Mahajan R, Kedia S et al. Use of thiopurines in inflammatory bowel disease: an update. Intest Res. 2022;20:11–30. https://doi.org/10.5217/ir.2020.00155 .
doi: 10.5217/ir.2020.00155
pubmed: 33845546
Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666. https://doi.org/10.1002/ibd.20520 .
doi: 10.1002/ibd.20520
pubmed: 18623174
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–1629. https://doi.org/10.1056/NEJM198712243172603 .
doi: 10.1056/NEJM198712243172603
pubmed: 3317057
Deepak P, Alayo QA, Khatiwada A et al. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19:1592-1601.e3. https://doi.org/10.1016/j.cgh.2020.06.050 .
doi: 10.1016/j.cgh.2020.06.050
pubmed: 32629130
Viscido A, Valvano M, Stefanelli G et al. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol. 2022;22:92. https://doi.org/10.1186/s12876-022-02157-5 .
doi: 10.1186/s12876-022-02157-5
pubmed: 35240984
pmcid: 8895505
Ayres RC, Gillen CD, Walmsley RS, Allan RN. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol. 1996;8:555–558. https://doi.org/10.1097/00042737-199606000-00011 .
doi: 10.1097/00042737-199606000-00011
pubmed: 8823569
Chaparro M, Acosta D, Rodríguez C et al. Real-world evidence of tofacinitib in ulcerative colitis: short-term and long-term effectiveness and safety. Am J Gastroenterol. 2023. https://doi.org/10.14309/ajg.0000000000002145 .
doi: 10.14309/ajg.0000000000002145
pubmed: 36716287
Long MD, Afzali A, Fischer M et al. Tofacitinib response in ulcerative colitis (TOUR): early response after initiation of tofacitinib therapy in a real-world setting. Inflamm Bowel Dis. 2022. https://doi.org/10.1093/ibd/izac121 .
doi: 10.1093/ibd/izac121
pubmed: 35040995
pmcid: 10069660
Pineton de Chambrun G, Amiot A, Bouguen G et al. Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative proctitis. Clin Gastroenterol Hepatol. 2020;18:620-627.e1. https://doi.org/10.1016/j.cgh.2019.05.060 .
doi: 10.1016/j.cgh.2019.05.060
pubmed: 31202984
Bouguen G, Roblin X, Bourreille A et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther 2010;31:1178–1185. https://doi.org/10.1111/j.1365-2036.2010.04293.x .
doi: 10.1111/j.1365-2036.2010.04293.x
pubmed: 20222911
Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SPL. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials. 2007;8:17. https://doi.org/10.1186/1745-6215-8-17 .
doi: 10.1186/1745-6215-8-17
pubmed: 17592647
pmcid: 1919394